# A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

> **NCT06956690** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hummingbird Bioscience** · enrollment: 180 (estimated)

## Conditions studied

- Melanoma (Skin)
- Non Small Cell Lung Cancer
- Breast Cancer

## Interventions

- **BIOLOGICAL:** ENV-501

## Key facts

- **NCT ID:** NCT06956690
- **Lead sponsor:** Hummingbird Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-17
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06956690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06956690, "A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06956690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*